Outlook Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.

CEO

C. Russell Trenary

CEOC. Russell Trenary

Employees

Employees17

Headquarters

Iselin, New Jersey

HeadquartersIselin, New Jersey

Founded

2010

Founded2010

Employees

Employees17

OTLK Key Statistics

Market cap

297.73M

Market cap297.73M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

731.84K

Average volume731.84K

High today

$1.17

High today$1.17

Low today

$1.11

Low today$1.11

Open price

$1.13

Open price$1.13

Volume

471.39K

Volume471.39K

52 Week high

$2.12

52 Week high$2.12

52 Week low

$0.6839

52 Week low$0.6839

OTLK Earnings

-$0.09

-$0.06

-$0.03

$0.00

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Estimated

-$0.04 per share

Estimated-$0.04 per share

Actual

Expected Feb 14, Pre-Market

ActualExpected Feb 14, Pre-Market

Outlook Therapeutics

Why Robinhood?

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. Show more

OTLK Key Statistics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.